# Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

> **NCT07264647** · PHASE2 · RECRUITING · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 30 (estimated)

## Conditions studied

- Stage III NSCLC

## Interventions

- **DRUG:** Tislelizumab
- **PROCEDURE:** surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- **RADIATION:** Chemoradiotherapy

## Key facts

- **NCT ID:** NCT07264647
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264647, "Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07264647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*